Gonzlez-Hernndez A, Marichal-Cancino BA, Lozano-Cuenca J, Lpez-Canales JS, Muoz-Islas E, Ramrez-Rosas MB, Villaln CM
An error in calculating your concentration will invalidate every single data point you collect
Book An Appointment Today Booking an appointment with Exclusive Med Aesthetics is effortless and convenient
Phase 1a: First-in-Human Single Ascending Dose Study (NCT02951806) Study Title: "Safety, Tolerability, and Pharmacokinetics of Single Doses of Cagrilintide in Healthy Subjects" Status: Completed Phase: Phase 1a Enrollment: 48 healthy volunteers Study Period: 2016-2017 Location: Single center (Denmark) Design: Randomized, double-blind, placebo-controlled, single ascending dose Dose Range: 0.03-10 mg SC Primary Endpoints: Safety, tolerability, PK parameters Population: Healthy male subjects, BMI 20-28 Key Results: Pharmacokinetics: Terminal half-life 5-7 days across dose range
Request a callback or speak to admissions if you want help choosing between online theory, VTCT study and hands-on training
Effects of folic acid on oligozoospermia with MTHFR polymorphisms in term of seminal parameters, DNA fragmentation, and live birth rate: a double-blind, randomized, placebo-controlled trial